Does any one out there know if we're going to phase 3 on Azixia. I know they just touted the results of their phase 2 study. Now what? Management seems perfectly content keeping their mouth shut instead of letting us know what's going on.
Azixa is being presented as a "salvage" drug. The path to approval for drugs in this category is not orderly. Management is probably negotiating with FDA over what will be required; it is expensive bad form to talk in public while negotiating with FDA. It is even possible that marketing will be permitted [for GBM] before anything designated "phase 3" is done.
The big money is in treatment of brain metastases of "the big 3" (lung, breast and colon cancers). For those to become label indications it will take LOTS more testing. But a little income stream in the mean time would be welcome [and off-label use might make that stream larger].
on the way, but will not go at it alone. looking for the right partner now. expect more phase 2 data and a partnership with time. i also expect a partnership on one of the other two drugs, one of those could even be first. that will slow burn.
With the FDA voting against VVUS today on Qeda, this breathes some air into MYRX's Nampt inhibitor as it is also being explored for weight loss. Who knows... this may end up being their "blockbuster". Stranger things have happened. Working to find a drug for cancer and found one for obesity instead!